These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31362797)

  • 21. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moderate physical exercise reduces parasitaemia and protects colonic myenteric neurons in mice infected with Trypanosoma cruzi.
    Moreira NM; Santos Fd; Toledo MJ; Moraes SM; Araujo EJ; Sant'Ana Dd; Araujo SM
    Int J Exp Pathol; 2013 Dec; 94(6):426-35. PubMed ID: 24205797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease.
    García MC; Ponce NE; Sanmarco LM; Manzo RH; Jimenez-Kairuz AF; Aoki MP
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3700-8. PubMed ID: 27067322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo.
    Gonçalves-Santos E; Caldas IS; Fernandes VÂ; Franco LL; Pelozo MF; Feltrim F; Maciel JS; Machado JVC; Gonçalves RV; Novaes RD
    Int Immunopharmacol; 2023 Aug; 121():110416. PubMed ID: 37295025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
    Ferraz ML; Gazzinelli RT; Alves RO; Urbina JA; Romanha AJ
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1359-64. PubMed ID: 17220408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection.
    Freitas VLT; Novaes CTG; Sartori AMC; Carvalho NB; Silva SCVD; Nakanishi ÉS; Salvador F; Castro CN; Bezerra RC; Westphalen EVN; Oliveira CMR; Busser FD; Ho YL; Buccheri R; Bonilla C; Shikanai-Yasuda MA
    PLoS Negl Trop Dis; 2024 Feb; 18(2):e0011961. PubMed ID: 38408095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of essential oil of Syzygium aromaticum alone and in combination with benznidazole on murine oral infection with Trypanosoma cruzi IV.
    Zanusso Junior G; Massago M; Kian D; Toledo MJO
    Exp Parasitol; 2018 Feb; 185():92-97. PubMed ID: 29305891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Treatment Outcomes of Antiparasitic Therapy in
    Albareda MC; Natale MA; De Rissio AM; Fernandez M; Serjan A; Alvarez MG; Cooley G; Shen H; Viotti R; Bua J; Castro Eiro MD; Nuñez M; Fichera LE; Lococo B; Scollo K; Tarleton RL; Laucella SA
    Front Immunol; 2018; 9():1958. PubMed ID: 30271399
    [No Abstract]   [Full Text] [Related]  

  • 33. Nonsteroidal anti-inflammatory is more effective than anti-oxidant therapy in counteracting oxidative/nitrosative stress and heart disease in T. cruzi-infected mice.
    Novaes RD; Santos EC; Fialho MDCQ; Gonçalves WG; Sequetto PL; Talvani A; Gonçalves RV
    Parasitology; 2017 Jun; 144(7):904-916. PubMed ID: 28134069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of diminazene aceturate on renin-angiotensin system, infectious myocarditis and skeletal myositis in mice: An in vitro and in vivo study.
    Souza-Silva TG; Vilas-Boas DF; Gonçalves-Santos E; Mazzeti AL; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Life Sci; 2020 Sep; 257():118067. PubMed ID: 32652140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.
    Novaes RD; Santos EC; Cupertino MC; Bastos DS; Oliveira JM; Carvalho TV; Neves MM; Oliveira LL; Talvani A
    Parasitol Res; 2015 Aug; 114(8):2873-81. PubMed ID: 25912691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
    Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
    Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical Exercise Promotes a Reduction in Cardiac Fibrosis in the Chronic Indeterminate Form of Experimental Chagas Disease.
    Pedra-Rezende Y; Barbosa JMC; Bombaça ACS; Dantas-Pereira L; Gibaldi D; Vilar-Pereira G; Dos Santos HAM; Ramos IP; Silva-Gomes NL; Moreira OC; Lannes-Vieira J; Menna-Barreto RFS
    Front Immunol; 2021; 12():712034. PubMed ID: 34804007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
    Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
    Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review.
    Carvalho NB; Freitas VLT; Seguro FS; Bezerra RC; Fatobene G; Nakanishi ÉYS; Visnadi H; Martinez G; Batista MV; Rocha V; Dulley FL; Costa SF; Shikanai-Yasuda MA
    Rev Inst Med Trop Sao Paulo; 2024; 66():e10. PubMed ID: 38324876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.